Phase 3 psilocybin and LSD data plus new FDA guidance fuel a depression boom—yet clinics still wrestle with dosing time, cost, access.
|Slideshows|August 10, 2018
5 Reports on Depression
Author(s)James Murrough, MD, PhD
This special collection provides new insights on major aspects of depression: psychopharmacology, therapeutic interventions, major depressive episodes, biomarkers, and pseudobulbar affect.
Advertisement
Advertisement
Related to this article
Ketamine, esketamine, and ECT can rapidly ease suicidal thoughts, but evidence for preventing attempts or deaths remains limited—see what’s proven.
Learn how clozapine, lithium, ketamine, and antidepressants fit into suicide prevention, from rapid crisis relief to long-term risk reduction.
Can hormones flag suicide risk in schizophrenia? Review links cortisol, thyroid and testosterone shifts—and clozapine/lithium pathways—to risk.
How VA clinicians treat veterans’ PTSD while managing suicide risk, using shared decisions, safety planning, and phase-based trauma therapies.
Helus Pharma advances oral deuterated psilocin HLP003 for MDD, detailing new efficacy and safety analyses plus ongoing phase 3 PARADIGM trial updates.
New real-world studies show Vraylar boosts depression relief, functioning, and quality of life in MDD and bipolar I patients beyond clinical trials.
Advertisement
Advertisement
Trending on Psychiatric Times
1
What Clinicians Need to Know About Postpartum Psychosis
2
Brain Trust: Therapeutic Drug Monitoring and Adherence in Schizophrenia, With Jonathan M. Meyer, MD
3
Nature vs Nurture: The Interplay Between Genetics and Environmental Influences
4
ACNP Position Paper Lays Out Roadmap for Biomarker-Guided Psychiatric Drug Trials
5